|
|||||
|
|
Bevacizumab Combined with S-1 and Raltitrexed for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies: A Phase II Study |
|
| Authors: | Ye Chen Yu-Wen Zhou Ke Cheng Zhi-Ping Li De-Yun Luo Meng Qiu Qiu Li Xin Wang Ya-Li Shen Dan Cao Yu Yang Feng Bi Ji-Yan Liu Hong-Feng Gou |
| Institution: | 1. Department of Abdominal Cancer, West China Hospital, West China Medical School, Sichuan University, Chengdu, People's Republic of China
Contributed equally;2. Department of Biotherapy, Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, People's Republic of China Contributed equally;3. Department of Abdominal Cancer, West China Hospital, West China Medical School, Sichuan University, Chengdu, People's Republic of China;4. Department of Biotherapy, Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, People's Republic of China |
| Abstract: | Lessons Learned
|
| Keywords: | Refractory metastatic colorectal cancer Bevacizumab S-1 Raltitrexed Drug resistance |